Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
There is a medical need for highly effective, safe, and well-tolerated treatments for patients infected with hepatitis C virus (HCV) Eight patients had serious adverse events, none of which were treatment-related. There were no treatment-related cardiac events or clinically significant changes in echocardiographic parameters or creatinine clearance.
